Measurement of procarboxypeptidase U (TAFI) in human plasma: A laboratory challenge

Clinical Chemistry

Volumn 52, Issue 1, 2006, Pages 30-36

  Willemse, Johan L ^a   Hendriks, Dirk F ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME PRECURSOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ANALYTIC METHOD; ANTIGEN DETECTION; CLINICAL PATHWAY; CONCENTRATION RESPONSE; DIAGNOSTIC VALUE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HUMAN; IMMUNOELECTROPHORESIS; LABORATORY DIAGNOSIS; MEASUREMENT; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SPECTROPHOTOMETRY; STANDARDIZATION; VALIDATION PROCESS;

CARBOXYPEPTIDASE U; ENZYME TESTS; HUMANS; IMMUNOASSAY; KINETICS; PLASMA; RISK FACTORS; THROMBIN; THROMBOMODULIN; THROMBOSIS;

EID: 29744453508     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.055814     Document Type: Short Survey

References (46)

1. Hendriks D, Scharpé S, van Sande M. Partial characterization of a new arginine carboxypeptidase from human serum. J Clin Chem Clin Biochem 1988;26:305.
2. Hendriks D, Scharpé S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989;27:277-85.
3. Hendriks D, Scharpé S, van Sande M, Lommaert MP. A labile enzyme in fresh human serum interferes with the assay of carboxypeptidase N [Technical Brief]. Clin Chem 1989;35:177.
4. Hendriks D, Wang W, van Sande M, Scharpé S. Human serum carboxypeptidase U: a new kininase? Agents Actions Suppl 1992;38:407-13.
5. Shinohara T, Sakurada C, Suzuki T, Takeuchi O, Campbell W, Ikeda S, etal. Pro-carboxypeptidase R cleaves bradykinin following activation. Int Arch Allergy Immunol 1994;103:400-4.
6. Kato K, Shinagawa N, Hayakawa T, Takeyama H, Campbell W, Okada H. Changes in arginine carboxypeptidase (CPR) activity in stressed rats. Pathophysiology 1994;1:131-6.
7. Wang W, Boffa MB, Bajzar L, Walker J, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998;273:27176-81.
8. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997;272:14477-82.
9. Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004;279:13333-9.
10. Schneider M, Brufatto N, Neill E, Nesheim M. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin. J Biol Chem 2004;279:13340-5.
11. Leurs J, Nerme V, Sim Y, Hendriks D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004;2:416-23.
12. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin activable fibrinolyis inhibitor is masked by its instability. J Biol Chem 2004;279:27896-904.
13. Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, et al. Procarboxypeptidase R is an acute phase protein in mouse, whereas carboxypeptidase N is not. J Immunol 2000;165:1053-8.
14. Boffa MD, Hamill JD, Maret D, Brown D, Scott ML, Nesheim ME, et al. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in Hep G2 cells. J Biol Chem 2003;278:9250-7.
15. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002;46:131-4.
16. Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001;180:162-6.
17. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003;278:51059-67.
18. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996;271:16603-8.
19. Schatteman K, Goossens F, Scharpé S, Hendriks D. Proteolytic activation of purified procarboxypeptidase U. Clin Chim Acta 2000;292:25-40.
20. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI dependent. Blood 1996;88:2093-100.
21. Mosnier LO, von-dem-Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998;80:829-35.
22. Stromqvist M, Schatteman K, Leurs J, Verkerk R, Andersson JO, Johansson T, et al. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost 2001;85:12-7.
23. Guo X, Morioka A, Kaneko Y, Okada N, Obata K, Nomura T, et al. Arginine carboxypeptidase (CPR) in human plasma determined with sandwich ELISA. Microbiol Immunol 1999;43:691-8.
24. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003;23:1122-7.
25. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000;95:2855-9.
26. Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998;80:949-55.
27. Brouwers GJ, Vos HL, Leebeek FW, Bulk S, Schneider M, Boffa M, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001;98:1992-3.
28. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002;277:1021-30.
29. Franco RF, Fagundes MG, Meijers JM, Reitsma PH, Lourenco D, Morelli V, et al. Identification of polymorphisms in the 5′ untranslated region of the TAFI gene: relationship with TAFI levels and risk of venous thrombosis. Haematologica 2001;86:510-7.
30. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001;97:2053-8.
31. Tani S, Akatsu H, Ishikawa Y, Okada N, Okada H. Preferential detection of pro-carboxypeptidase R by enzyme-linked immunosorbent assay. Microbiol Immunol 2003;47:295-300.
32. Guimaraes AHC, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004;124:659-65.
33. Hendriks D, Scharpé S, van Sande M. Assay of carboxypeptidase N activity in serum by liquid chromatographic detection of hippuric acid. Clin Chem 1985;12:1936-9.
34. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000;275:12868-78.
35. Schatteman K, Goossens F, Scharpé S, Hendriks D. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999;45:807-13.
36. Willemse J, Leurs J, Verkerk R, Hendriks D. Development of a fast kinetic method for the determination of carboxypeptidase U using C-terminal arginine containing peptides as substrate. Anal Biochem 2005;340:106-12.
37. Willemse JL, Leurs JR, Hendriks DF. Fast kinetic assay for the determination of procarboxypeptidase U (TAFI) in human plasma. J Thromb Haemost 2005;3:2353-5.
38. Hendriks D, Van Sande M, Scharpé S. Colorimetric assay for carboxypeptidase N in serum. Clin Chim Acta 1986;157:103-8.
39. Hendriks D, Scharpé S, van Sande M, Lommaert MP, Kasahara Y. Carboxypeptidase N: colorimetric assay using a new substrate. Anal Biochem 1987;164:90-5.
40. Schatteman K, Goossens F, Leurs J, Kasahara Y, Scharpé S, Hendriks D. Fast and homogeneous assay for plasma procarboxypeptidase U. Clin Chem Lab Med 2001;39:806-10.
41. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombo-modulin dependent activation, thermal stability and enzymatic properties. J Biol Chem 1998;273:2127-35.
42. Plummer TH, Kimmel MT. An improved spectrophotometric assay for human carboxypeptidase N. Anal Biochem 1980;108:348-53.
43. Mock WL, Xu D. Catalytic activity of carboxypeptidase B and of carboxypeptidase Y with anisylazoformyl substrates. Bioorg Med Chem Lett 1999;9:187-92.
44. Mock WL, Stanford DJ. Anisylazoformylarginine: a superior assay substrate for carboxypeptidase B type enzymes. Bioorg Med Chem Lett 2002;12:1193-4.
45. Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Stromqvist M, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000;84:364-8.
46. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002;22:867-73.